6 products were found matching "443913-73-3"!

Description: Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 (IC50: 40 nM). It also inhibits VEGFR3 and EGFR. Target: Apoptosis, Autophagy, EGFR, VEGFR. Smiles: COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1. References: Wedge SR, et al. ZD6474 inhibits vascular endothelial growth factor signaling,...

Vandetanib is a multi-kinase inhibitor that inhibits VEGFR2, VEGFR3, VEGFR1, EGFR, PDGFRbeta, Tie-2, and FGFR1 in cell-free assays (IC50s = 40, 110, 1,600, 500, 1,100, 2,500, and 3,600 nM, respectively). It also binds to 142 additional kinases in a panel of 442 kinases (Kds = 4.6-7,900 nM). Vandetanib (1 and 2.5 µM)...

Is an inhibitor of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR).

Vandetanib inhibits VEGFR-dependent tumor angiogenesis and EGFR- and RET-dependent tumor cell proliferation and survival. Solubility: Soluble in DMSO at 30mg/ml, soluble in ethanol at 10mg/ml with warming, very poorly soluble in water, maximum water solibility is estimated to be about 10-20uM, buffers, serum, or...

Soluble in DMSO or ethanol. Vandetanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR, IC(50) of 40nM) and the epidermal growth factor receptor (EGFR). Target: EGFR - VEGFR2 , Kinase Group: RTK , Substrate: Tyrosine

Vandetanib is an orally available, ATP mimetic small molecule tyrosine kinases inhibitor that targets vascular endothelial growth factor receptor-2 (VEGFR-2), VEGFR-3 and epidermal growth factor receptor (EGFR), REarranged during Transfection (RET) and slightly VEGFR-1. Inhibition of these tyrosine kinases blocks...